Why So Few New Cardiovascular Drugs Translate to the Clinics

Abstract

There are multiple reasons for the failure to successfully translate new drugs to the clinics. One reason, noted by others, is the lack of reproducibility of studies and the problems with accuracy and rigor. However, another reason for translational failure has not been emphasized by others, i.e., the lack of state-of-the-art cardiovascular measurements, due to effects of anesthesia, lack of direct measurements of cardiovascular function, and problems of species differences. In part, this is due to the impact of molecular medicine on traditional physiology, which not only affects priority for publication in top tier journals, but also funding priorities for NIH study sections, resulting in the closure of almost all cardiovascular physiology laboratories, leaving the cardiovascular physiology in many molecular publications to incidental data that are not peer reviewed and in many cases are inaccurate. It is the plea of this Viewpoint to correct this deficiency in expertise in our scientific community, a project with no simple solutions.

Keywords: academic fraud; cardiovascular physiology; pharmacology.

Figure 1